<b>Warburg Pincus acquires therapy-focused formulations platform Integrace for ₹1,200 crore in full exit of True North and Temasek</b>

PE / VC 15 Jul 2026· ₹1,200 cr · Completed· ✓ Verified

Integrace, incorporated August 2018, built its portfolio through acquisitions of Glenmark's orthopedic (₹635 cr) and gynecology (₹115 cr) businesses, plus Zydus Healthcare's Mifegest and Cytolog gynecology brands (2021). The company operates 20+ brands including power-brands Lizolid, Stiloz, Mifegest, and Cytolog, serving 45,000+ healthcare professionals. Warburg Pincus now adds this to its portfolio alongside Metropolis, Laurus Labs, MedPlus, Meril Life Sciences, and Appasamy Associates across three decades of Indian healthcare investment.

Why it mattersThe transaction demonstrates a PE playbook of consolidating specialty-therapy formulations platforms through leadership transitions (Rehan Khan appointed CEO from MSD/Abbott India) and multi-strand diligence spanning pharma regulation, compliance, ESOP structuring, and IP-signalling institutional investor comfort with niche India pharma.
CounselCyril Amarchand Mangaldas, Khaitan & Co, JSA Advocates & Solicitors
SectorPharma & Healthcare
Value₹1,200 cr
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals